Category: vaccine
-
WHO clears Bavarian Nordic’s vaccine as first mpox shot By Reuters
•
By Jennifer Rigby and Manas Mishra The World Health Organization said on Friday it had approved Bavarian Nordic’s Mbox vaccine, the first of its kind approved by the agency to contain the spread of the disease in hard-hit African countries. The approval, known as prequalification, comes as a new variant…
-
Emergent stock jumps as FDA clears smallpox vaccine for people at high risk of mpox (NYSE:EBS)
•
Emerging Bio-Solutions (New York: EBS) stocks jumped 23% pre-market Friday The U.S. Food and Drug Administration (FDA) has approved expanded use of the company’s ACAM2000 smallpox vaccine to include people at risk of smallpox infection. Earlier this month, the World Health Organization announced The outbreak of monkeypox, formerly known as…
-
Emergent stock jumps as FDA clears smallpox vaccine for people at high risk of mpox (NYSE:EBS)
•
Emerging Bio-Solutions (New York: EBS) stocks jumped 23% pre-market Friday The U.S. Food and Drug Administration (FDA) has approved expanded use of the company’s ACAM2000 smallpox vaccine to include people at risk of smallpox infection. Earlier this month, the World Health Organization announced The outbreak of monkeypox, formerly known as…
-
AstraZeneca warns of moving UK vaccine production to US, FT reports By Reuters
•
(Reuters) – AstraZeneca has warned it may move vaccine manufacturing from the United Kingdom to the United States amid a standoff with the new Labour government over plans to cut state aid, the Financial Times reported on Thursday. UK finance minister Rachel Reeves wants to cut government funding for the…
-
AstraZeneca’s £450 million vaccine plant at risk as government reconsiders financial backing
•
The US Treasury has confirmed it remains in “positive discussions” with AstraZeneca over the pharmaceutical giant’s proposed £450m vaccine manufacturing facility in northwest England. However, doubts have emerged following reports that the government is considering cutting its financial support for the project to £40m – a significant cut from the…
-
Moderna cuts 2024 sales forecast, sees low EU vaccine revenue into 2026 By Reuters
•
By Patrick Wingrove and Leroy Liu (Reuters) – Moderna Inc on Thursday cut its 2024 sales forecast for its COVID-19 and respiratory syncytial virus vaccines by about 25%, or $1 billion, due to lower COVID sales to the European Union that it expects to continue through 2026. Shares of the…
-
Gritstone bio details progress in cancer vaccine trials By Investing.com
•
Gritstone bio (GRTS) has unveiled promising preliminary data from its GRANITE personalized cancer vaccine program during its First Quarter 2024 Earnings Call. The clinical updates showed a positive trend in progression-free survival (PFS) for colorectal cancer patients, with particularly encouraging results in high-risk individuals. The company’s financial position was also…